LATEST

• REGULATORY Outgoing MHLW Pharmacy Chief Eyes AI as Next Frontier for Drug Regulation
  August 4, 2026

• REGULATORY Takeda’s Orzeyful Inches Closer to Japan Approval as 1st NT1 Drug
  August 4, 2026

• BUSINESS Lilly Blasts Mounjaro Price Cut, Warns over Japan Investment Appeal
  August 4, 2026

• BUSINESS Leqembi Leads US Anti-Amyloid Market; Eisai Sees Iqlik Reshaping AD Care
  August 4, 2026

• BUSINESS Shionogi Highlights ViiV’s Long-Term HIV IP Strategy
  August 4, 2026

• BUSINESS Kyowa Kirin Profits Surge as R&D Costs Fall, Overseas Sales Grow
  August 4, 2026

• REGULATORY MHLW Gives Fuel Priority to Drug Deliveries in Quake-Hit Kumamoto
  August 4, 2026

• BUSINESS Kyorin to Begin Co-Promoting Alesion Eyelid Cream on August 17
  August 4, 2026

• BUSINESS Fujifilm, Taiho Forge Strategic Partnership on ADC Manufacturing
  August 4, 2026

• BUSINESS Celltrion to Launch 1st Stelara IV Biosimilar on August 20
  August 4, 2026

• BUSINESS BMS Files Obexelimab in Japan for IgG4-Related Disease
  August 4, 2026

• COMMENTARY Signs of Shift in Japan’s Drug Policy, but Cost Pressures Persist
  August 3, 2026

• BUSINESS Viatris Recalls Sevoflurane Anesthetic over Manufacturing Deviation
  August 3, 2026

• BUSINESS Belite Bio Japan Launches Stargardt Disease Awareness Initiative
  August 3, 2026

• BUSINESS Otsuka Eyes 3.5 Trillion Yen Sales by 2035 on New Growth Drivers
  August 3, 2026

• BUSINESS Daiichi Sankyo Cuts FY2027 Net Profit Outlook on Higher Tax Burden
  August 3, 2026

• BUSINESS Kissei Slashes Tavneos Sales Forecast after Safety, Data Concerns
  August 3, 2026

• REGULATORY Unami Tapped as Japan’s New Top Finance Bureaucrat
  August 3, 2026

• BUSINESS Forxiga Exit Weighs on Ono’s Japan Sales, but Boosts Profit
  August 3, 2026

• BUSINESS Bayer, JFCR Ink Strategic Oncology R&D Partnership
  August 3, 2026

ページ

• « 先頭
• ‹ Prev
• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• …
• Next ›
• 最終 »